Sam Rasty, PhD, is a biopharma executive with 30 years of experience in biotechnology and pharmaceuticals. A strategic and operational leader with deep scientific and business expertise in life sciences, Sam’s career has spanned drug discovery and development, clinical trials, regulatory strategy, marketing, new product planning, manufacturing, payer & reimbursement policy, commercial launch, fundraising, business development, partnering, licensing and M&A. His varied leadership roles in large pharma, midcap biotech and emerging life science start-ups provide him with a unique perspective into the biopharma ecosystem.
Sam Rasty
Partner
- Boston,
- MA
Healthcare, Life Sciences/Pharma
Sam Rasty, PhD, is a biopharma executive with 30 years of experience in biotechnology and pharmaceuticals.
About Sam
Career Highlights
- RESULT #1: President & CEO of PlateletBio, a preclinical cell therapy company in Boston. Led the strategic pivot and expansion of the platform to autoimmunity, hematology and beyond, built a development-focused organization, advanced R&D and manufacturing capabilities, negotiated and closed a $56M contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) and raised a $75M Series B equity plus debt financing round.
- RESULT #2: Chief Operating Officer (employee #2) of Homology Medicines, helping to launch and build the company as a next-generation gene editing & gene therapy biotech in Q1 2016, taking the company to its successful $165M IPO in Q1 2018 and start of clinical trials in 2019. Engineered, drove, negotiated and closed Homology’s first major R&D collaboration deal with Novartis in 2017 ($50M upfront, ~$1B milestones, royalties and profit sharing) ahead of the IPO.
- RESULT #3: Built and led the New Products function in the Rare Diseases Business Unit of Shire Pharmaceuticals, laying out the strategy for Shire’s growth in various disease areas and helping to drive several in-licensing and M&A transactions in orphan diseases. With significant experience in orphan disease R&D, product development and commercialization, authored Shire’s commercial strategy in gene therapy.
- 215-534-7420
- sam.rasty@newportllc.com
- LinkedIn Profile
Areas of
Engagement
Engagement
- Corporate Strategy
- Leadership & Governance
- Acquisitions & Post-Merger Integration
